非戈替尼对活动性强直性脊柱炎患者12周骶髂关节MRI结构病变的影响:TORTUGA试验
TORTUGA试验的事后分析评估了非戈替尼(优先抑制JAK1)对活动性强直性脊柱炎患者骶髂关节MRI结构改变的影响。87例患者(非戈替尼48例,安慰剂39例)的MRI扫描显示,12周时非戈替尼组骶髂关节侵蚀评分显著降低(P=0.02),回填评分显著增加(P=0.005),而强直和脂肪化生无显著组间差异。结论提示JAK1优先抑制剂治疗后可早期观察到组织修复。
要点
- 非戈替尼治疗12周可显著降低骶髂关节MRI侵蚀评分并增加回填评分。
- 强直和脂肪化生评分在12周时未见显著组间差异。
- MRI炎症评分变化与侵蚀评分正相关、与回填评分负相关。
核心结论
- 非戈替尼在12周内诱导骶髂关节MRI结构病变的显著变化,提示JAK1优先抑制剂治疗后可早期观察到组织修复,可能对强直发展有预后意义。
研究设计与样本
- TORTUGA试验的事后分析,纳入活动性强直性脊柱炎且对至少两种NSAIDs应答不足或不耐受的成人患者,随机1:1接受非戈替尼200 mg(n=58)或安慰剂(n=58)每日一次治疗12周。
- 对骶髂关节T1加权MRI扫描由两名独立阅片者采用SPARCC SSS定义评估侵蚀、回填、脂肪化生和强直。
主要发现
- 87例患者(非戈替尼48例,安慰剂39例)的MRI扫描被评估。
- 基线时非戈替尼与安慰剂在任何MRI结构病变类型上无显著差异。
- 从基线至第12周,非戈替尼组较安慰剂组骶髂关节侵蚀评分显著降低(P=0.02),回填评分显著增加(P=0.005)。
- 强直(P=0.46)和脂肪化生(P=0.17)无显著组间差异。
- 第12周时SPARCC MRI骶髂关节炎症评分变化与侵蚀评分正相关,与回填评分负相关。
关键数值与推荐
- 非戈替尼200 mg每日一次治疗12周,与安慰剂相比,侵蚀评分变化P=0.02,回填评分变化P=0.005。
- 强直评分变化P=0.46,脂肪化生评分变化P=0.17。
临床怎么用
- 对于活动性强直性脊柱炎患者,非戈替尼治疗12周即可在MRI上观察到骶髂关节侵蚀减少和回填增加,提示早期组织修复。
- MRI结构病变的变化可能有助于评估JAK1优先抑制剂对强直进展的预后影响。
局限性
- 本文为事后分析,样本量有限(87例MRI可评估),需谨慎解读。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial. METHODS: Adults with active AS and inadequate response/intolerance to two or more NSAIDs were randomized 1:1 to filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, T1-weighted MRI scans of the SI joint were evaluated by two independent readers using Spondyloarthritis Research Consortium of Canada (SPARCC) Sacroiliac Joint Structural Score (SSS) definitions for erosion, backfill, fat metaplasia and ankylosis. Correlations between SPARCC SSS and improvement in clinical outcomes were also assessed. RESULTS: MRI scans from 87 patients (48 filgotinib, 39 placebo) were evaluated. At baseline there were no notable differences between filgotinib and placebo for any MRI structural lesion types. From baseline to week 12, filgotinib was associated with a significant reduction in SI joint erosion score (P = 0.02) and an increase in backfill score (P = 0.005) vs placebo, with no significant between-group differences for ankylosis (P = 0.46) or fat metaplasia (P = 0.17). At week 12, the change in SPARCC MRI SI joint inflammation scores correlated positively with erosion scores but negatively with backfill scores. CONCLUSION: The significant changes in MRI structural lesions induced by filgotinib in the SI joint by week 12 demonstrate that tissue repair can be observed very soon after starting treatment with a JAK1 preferential inhibitor. This could have prognostic implications for development of ankylosis. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03117270.
引用
- Maksymowych WP, Østergaard M, Landewé R, et al. Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial). Rheumatology (Oxford). 2022. PMID: 34352069. doi:10.1093/rheumatology/keab543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。